Growth Metrics

Dexcom (DXCM) Depreciation & Amortization (CF) (2016 - 2026)

Dexcom has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $67.1 million for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 11.83% to $67.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $258.9 million through Mar 2026, up 14.96% year-over-year, with the annual reading at $251.8 million for FY2025, 15.66% up from the prior year.
  • Depreciation & Amortization (CF) was $67.1 million for Q1 2026 at Dexcom, up from $65.2 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $67.1 million in Q1 2026 and troughed at $36.3 million in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $52.5 million (2023), against an average of $51.7 million.
  • Year-over-year, Depreciation & Amortization (CF) soared 85.53% in 2022 and then grew 0.23% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $36.3 million in 2022, then soared by 44.63% to $52.5 million in 2023, then rose by 10.1% to $57.8 million in 2024, then grew by 12.8% to $65.2 million in 2025, then increased by 2.91% to $67.1 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Depreciation & Amortization (CF) are $67.1 million (Q1 2026), $65.2 million (Q4 2025), and $63.6 million (Q3 2025).